Sino Biopharmaceutical Limited

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:39 2024-05-28 am EDT			5-day change	1st Jan Change
2.88 ^HKD	+1.41%		-7.99%	-17.00%

May. 24	Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials	MT
May. 23	Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma	CI

Sino Biopharmaceutical Limited Announces Executive Changes

August 21, 2020 at 12:01 am EDT

The board of directors of Sino Biopharmaceutical Limited announces that Mr. Tse Ping has been re-designated as the senior vice chairman of the Board of the Company and Mr. Li Yi has been appointed as an executive director with effect from August 19, 2020.

Latest news about Sino Biopharmaceutical Limited

Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials	May. 24	MT
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma	May. 23	CI
Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%	May. 09	MT
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China	May. 09	CI
Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets	Apr. 30	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules	Apr. 30	CI
Sino Biopharm Completes Phase I Study of Hepatitis B Drug	Apr. 25	MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets	Apr. 22	MT
Hong Kong shares jump on policy support; China slips	Apr. 22	RE
Hong Kong shares jump 1.5% on policy support; China slips	Apr. 22	RE
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug	Apr. 19	MT
Sino Biopharmaceutical Limited Announces Category 1 Innovative Drug Rovadicitinib Obtained Positive Results in Key Clinical Research for Registration	Apr. 18	CI
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares	Apr. 17	MT
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	Apr. 10	MT
Sino Biopharmaceutical Trustee Repurchases Shares	Apr. 08	MT
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China	Apr. 08	MT
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China	Apr. 07	CI
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023	Mar. 29	MT
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024	Mar. 28	CI
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China	Mar. 24	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Iopromide Injection	Mar. 24	CI
Sino Biopharmaceutical's Developing Two Drugs for MASH	Mar. 15	MT
Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy	Mar. 15	MT
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"	Mar. 15	CI

Chart Sino Biopharmaceutical Limited

Duration

Period

More charts

Company Profile

Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).

Sector

Pharmaceuticals

Calendar

2024-06-10 - Final dividend

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for Sino Biopharmaceutical Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.672 CNY

Average target price

4.256 CNY

Spread / Average Target

+59.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SINO BIOPHARMACEUTICAL LIMITED	-17.00%	6.67B
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.66%	328B
ABBVIE INC.	+0.24%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	164B
PFIZER, INC.	-1.70%	164B

Other Pharmaceuticals